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Abstract
Background: Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a heterogeneous group of
aggressive T-cell lymphomas with poor treatment outcomes. The aim of this study was to evaluate whether
lymphopenia at diagnosis would have an adverse effect on survival in patients with PTCL-NOS treated with
anthracycline-containing chemotherapy.
Methods: A total of 118 patients with PTCL-NOS treated with anthracycline-containing chemotherapy from 4
Korean institutions were included.
Results: Thirty-six patients (30.5%) had a low absolute lymphocyte count (ALC, < 1.0 × 109/L) at diagnosis. Patients
with lymphopenia had shorter overall survival (OS) and progression-free survival (PFS) rates compared with patients
with high ALCs (P = 0.003, P = 0.012, respectively). In multivariate analysis, high-intermediate/high-risk International
Prognostic Index (IPI) scores and lymphopenia were both associated with shorter OS and PFS. Treatment-related
mortality was 25.0% in the low ALC group and 4.8% in the high ALC group (P = 0.003). In patients considered
high-intermediate/high-risk based on IPI scores, lymphopenia was also associated with shorter OS and PFS (P =
0.002, P = 0.001, respectively).
Conclusion: This study suggests that lymphopenia could be an independent prognostic marker to predict
unfavorable OS and PFS in patients with PTCL-NOS treated with anthracycline-containing chemotherapy and can
be used to further stratify high-risk patients using IPI scores.
Keywords: peripheral T-cell lymphoma, not otherwise specified, lymphopenia, international prognostic index,
prognostic factor
Background
Peripheral T-cell lymphomas (PTCL) account for
approximately 12% to 15% of all non-Hodgkin’s lympho-
mas in Western countries and 15% to 20% in Asian coun-
tries [1,2]. Peripheral T-cell lymphoma, not otherwise
specified (PTCL-NOS), is the most common heteroge-
neous subgroup of PTCL because it includes lymphomas
with no definitive clinical or biologic profile and it cannot
be classified into a specific subtype [3]. PTCL-NOS is a
highly aggressive lymphoma with a poor response to
conventional chemotherapy and a 5-year overall survival
(OS) of about 25% to 45% [4]. Anthracycline-containing
chemotherapy, such as CHOP (cyclophosphamide,
doxorubicin, vincristine and prednisone) or CHOP-like
regimens, are considered to be standard therapy for
PTCL-NOS, although remission rates are less than satis-
factory [1]. More intensive regimens, such as hyper-
CVAD (hyperfractionated cyclophosphamide, vincristine,
doxorubicin, and dexamethasone) and hyper-CHOP,
have not shown improved outcomes compared with
CHOP regimens [5]. Several prognostic factors, including
the International Prognostic Index (IPI), Prognostic
Index for T-cell lymphoma (PIT), and International Per-
ipheral T-cell Lymphoma Project (IPTCLP), have been
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suggested as methods to determine prognostic factors for
outcomes with PTCL-NOS [6-9]. In addition, biologic
markers such as nuclear factor (NF)-B and cytochrome
P4503A4 isoenzymes have been proposed; however, they
do not stratify PTCL-NOS completely [3,10-12]. As a
result, there is no single or simple clinical or biologic
parameter for predicting treatment outcomes, except for
IPI, in patients with PTCL-NOS. Because previous prog-
nostic markers, such as IPI, have been based on informa-
tion from all patients with PTCL-NOS regardless of
chemotherapy regimen used, the role of IPI needs to be
evaluated in patients treated with similar chemotherapy
regimens. This would allow for identification of addi-
tional simple prognostic markers in the same population
of patients.
Lymphopenia measured by absolute lymphocyte count
(ALC) at diagnosis has been studied as an independent
prognostic factor for poor survival in many hematologic
malignancies, including Hodgkin’s disease, diffuse large
B-cell lymphoma (DLBCL), and follicular lymphoma
[13-19]. In addition, it is known as a poor prognostic
marker in solid tumors such as metastatic breast cancer
and sarcomas [18]. Lymphopenia can also be used as a
predictable marker for the relapse after chemotherapy;
lymphocyte recovery after chemotherapy and autologous
hematopoietic stem cell transplantation (ASCT) can
help predict clinical outcomes in DLBCL patients
[20,21]. A few studies have reported the clinical impact
of lymphopenia in T-cell lymphoma. Recently, the role
of lymphopenia at diagnosis was suggested as a powerful
predictor of unfavorable treatment outcomes in extrano-
dal natural killer/T-cell lymphoma (ENKL) [22]. Because
there is no information on the role of lymphopenia at
diagnosis of PTCL-NOS, we evaluated its prognostic
value in the patients with PTCL-NOS treated with simi-
lar chemotherapy regimens. The objective of this study
was to retrospectively investigate whether lymphopenia
is a predictive marker for survival in patients with
PTCL-NOS treated with anthracycline-containing
chemotherapy.
Patients and methods
Patients
Patients diagnosed with PTCL between January 2000
and December 2009 from 4 Korean institutions were
evaluated for inclusion into the study. Patients with a
diagnosis of PTCL other than PTCL-NOS, such as ana-
plastic large cell lymphoma, angioimmunoblastic T-cell
lymphoma, enteropathy-associated T-cell lymphoma,
ENKL, subcutaneous panniculitis-like T-cell lymphoma,
primary cutaneous T-cell lymphoma (e.g., mycosis fun-
goides) were excluded. Specific extranodal presentations
of PTCL-NOS including primary central nervous system
(CNS) lymphoma or primary cutaneous lymphoma were
also excluded. Among 169 patients with PTCL-NOS
screened, 21 were excluded for the following reasons:
2 patients for double primary cancer, 5 for up-front
ASCT, 4 for primary CNS lymphoma, 5 for primary
cutaneous lymphoma, and 5 for incomplete clinical data.
Another 15 (8.9%) patients who did not receive che-
motherapy because of poor performance status, com-
bined comorbidity, or patient refusal were also excluded.
A total of 133 patients received systemic chemotherapy.
Of these, 118 (88.7%) patients were treated with anthra-
cycline-containing chemotherapy (e.g., CHOP or CHOP-
like regimens) as first-line treatment and 15 (11.3%)
were treated without anthracycline-containing che-
motherapy (e.g., IMEP [ifosfamide, etoposide, metho-
trexate, prednisone]). Therefore, 118 patients were
included in the trial.
Medical records were retrospectively reviewed for patient
demographics. These included age (< 60 vs. ≥ 60 years),
gender (male vs. female), Eastern Cooperative Oncology
Group (ECOG) performance status (0-1 vs. 2-4), the pre-
sence of B symptom (present vs. absent), Ann Arbor stage
(1-2 vs. 3-4), the number of extranodal sites involved (0-1
vs. ≥ 2), bone marrow involvement (positive vs. negative),
lactic dehydrogenase (LDH) concentrations (normal vs. ele-
vated), ALC (≥ 1.0 × 109/L vs. < 1.0 × 109/L), and prognos-
tic scores such as IPI (low risk/low-intermediate risk vs.
high-intermediate/high risk) and PIT (group 1-2 vs. group
3-4). For this study, lymphopenia was defined as an ALC
less than 1.0 × 109/L. Complete blood counts (CBC) with
differential and chemistry were performed at the time of
diagnosis and prior to treatment. No patients showed clini-
cal signs of severe infection at the time of laboratory test-
ing. The study protocol was approved by the institutional
review board from each participating institution.
Prognostic scores
IPI scores were based on age, ECOG performance status,
LDH concentrations, the number of extranodal sites
involved, and Ann Arbor stage as described above [9].
Four risk groups were defined by IPI score: 0 to 1, low
risk; 2, low-intermediate risk; 3, high-intermediate risk;
and 4 to 5, high risk. PIT scores were calculated using age,
ECOG performance status, LDH, and bone marrow invol-
vement as described above. Four risk groups were defined
by PIT scores: 0, group 1; 1, group 2; 2, group 3; and 3 to
4, group 4 [6].
Treatment and response
Anthracycline-containing chemotherapy included CHOP
(n = 98), CHOP-like regimens (n = 14), ProMACE/Cyta-
BOM (prednisone, cyclophosphamide, doxorubicin, etopo-
side, cytarabine, bleomycin, vincristine, and methotrexate;
n = 2), CAVOP (cyclophosphamide, doxorubicin, etopo-
side, vincristine, and prednisolone; n = 2), or hyper-CVAD
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(n = 2). Tumor response was defined as a complete
response (CR), partial response (PR), stable disease, and
progressive disease according to the International Work-
shop criteria [23]. Overall response rate (ORR) was defined
as the proportion of patients achieving a PR or better.
Statistical methods
The significance for categorical variables was calculated
using the chi-square test. Continuous variables were com-
pared by the t-test. Overall survival (OS) was measured
from the first date of diagnosis until death from any cause,
with surviving patients censored at the last follow-up date.
Progression-free survival (PFS) was defined as the time
from the date of diagnosis until disease progression,
relapse after response, or death due to lymphoma or treat-
ment. Death from other causes or survival at last follow-
up were censored. Survival curves were plotted by the
Kaplan-Meier method and compared using the log-rank
test. The influence of each prognostic factor identified by
univariate analysis was assessed by multivariate analysis
using Cox proportional-hazards regression stepwise
method. A P-value < 0.05 was considered statistically
significant for all analyses. All statistical analyses were per-
formed using SPSS for Windows, Version 18.0.
Results
Patient characteristics
A total of 118 patients were treated with anthracycline-
containing chemotherapy. The study group consisted of
79 males (66.9%) and 39 females (33.0%) with a median
age of 56 years (range, 20-86 years). Fourteen (11.8%)
patients presented with a poor performance status, and 32
(27.1%) had B symptoms at diagnosis. Seventy-nine
(66.9%) patients had stage III or IV advanced disease. The
number of patients with extranodal involvement at more
than 1 sites and involvement of bone marrow were 35
(29.6%) and 33 (27.9%), respectively. Sixty-one (51.6%)
patients had elevated LDH. For IPI scores, 44 (37.3%)
patients were classified as low risk, 31 (26.3%) as low-
intermediate risk, 30 (25.4%) as high-intermediate risk,
and 13 (11.0%) as high risk. For PIT scores, 30 (25.4%)
patients were classified in group 1, 43 (36.4%) in group 2,
28 (23.7%) in group 3, and 17 (14.4%) in group 4.
Clinical characteristics according to absolute lymphocyte
count
The median ALC was 1.32 × 109/L (range, 0.039-5.03 ×
109/L). Patients were divided into 2 groups according to
ALC (≥ or < 1.0 × 109/L). The proportion of patients
with a low ALC was 30.5% (36 of 118 patients). For
patients classified as having a high ALC (n = 82), the
median level was 1.78 × 109/L (range, 1.04-5.03 × 109/L).
Patients with low ALC (n = 36) had a median level of
0.69 × 109/L (range, 0.039-0.98 × 109/L). The clinical
characteristics of patients according to ALC are shown in
Table 1. The following characteristics were similar
between the 2 groups: age, gender, performance status,
presence of B symptom, Ann Arbor stage, number of
extranodal sites involved, and involvement of bone mar-
row. The average number of cycles of first-line che-
motherapy given was lower in low ALC group compared
with the high ALC group (P = 0.007). Elevated LDH,
high-intermediate/high risk IPI scores and high PIT
scores were correlated with a low ALC (P = 0.031, P =
0.043, P = 0.010, respectively).
Response according to absolute lymphocyte count
Among the 118 patients who were treated with anthra-
cycline-containing chemotherapy, 105 were evaluable for
treatment response. Fifty-six (47.4%) patients achieved a
CR and 78 (66.1%) achieved a PR or better. The CR rate
Table 1 Patient characteristics according to absolute
lymphocyte count
High ALC
(N = 82)
Low ALC
(N = 36)
P-value
Age
< 60 vs. ≥ 60 years 51/31 21/15 0.692
Gender
Male vs. Female 55/27 24/12 0.966
Performance status
0-1 vs. 2-4 74/8 30/6 0.355
B symptom
Present vs. Absent 21/61 11/25 0.578
Stage
1-2 vs. 3-4 31/51 8/28 0.098
Extranodal involvement
0-1 vs. ≥ 2 62/20 21/15 0.059
Bone marrow involvement
Positive vs. Negative 21/61 12/24 0.389
LDH
Normal vs. Elevated 45/37 12/24 0.031
IPI
L, LI vs. HI, H 57/25 18/18 0.043
PIT
Group 1-2 vs. 3-4 57/25 16/20 0.010
CR
CR vs. non-CR 42/37 14/12 0.952
Response (≥ PR)
Responder vs. Non-responder 61/18 17/9 0.231
TRM during the 1st line chemotherapy
Yes vs. No 4/78 9/27 0.003
Cycles of 1st line Chemotherapy
Median, range 6 (1-8) 3 (1-9) 0.007
LDH, lactate dehydrogenase; IPI, International Prognostic Index; L, low; LI, low-
intermediate; HI, high-intermediate; H, high; PIT, Prognostic Index for
peripheral T-cell lymphoma; CR, complete response; PR, partial response; TRM,
treatment related mortality; ALC, absolute lymphocyte count.
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was 53.2% (42 of 79 patients) and the ORR was 78.2%
(61 of 79 patients) in the high ALC group. For the low
ALC group, the CR rate was 53.8% (14 of 26 patients)
and the ORR was 65.4% (17 of 26 patients). There were
no statistically significant differences in the CR rate and
ORR based on ALC (Table 1).
Overall survival and progression-free survival analysis
The median duration of follow-up was 27.6 months
(range, 1.0-69.2 months). Sixty (50.8%) patients died dur-
ing the follow-up period. The rate of treatment-related
mortality (TRM) during first-line anthracycline-containing
chemotherapy was 11.0% (13 of 118 patients); 25.0% (9 of
36 patients) in low ALC group and 4.8% (4 of 82 patients)
in high ALC group (P = 0.003). The 3-year estimate for
OS was 48.5% and PFS was 35.0%.
The median OS was longer in patients with high
ALCs compared to those with low ALCs (69.4 months
vs. 15.5 months, P = 0.003; Figure 1A). In univariate
analysis, the following variables were associated with an
unfavorable OS: poor performance status (P < 0.001),
number of extranodal sites involved ≥ 2 (P = 0.005), ele-
vated LDH (P < 0.001), high-intermediate/high risk IPI
(P < 0.001), and PIT groups 3, 4 (P < 0.001; Table 2). In
multivariate analysis, IPI (hazard ratio [HR] 4.06, 95%
CI 2.40-6.84, P < 0.001) and lymphopenia (HR 2.24, 95%
CI 1.33-3.78, P = 0.002) were independent prognostic
factors for predicting OS in patients with PTCL-NOS
(Table 3).
The median PFS was longer in patients with high ALCs
compared to those with low ALCs (18.1 months vs. 7.0
months, P = 0.012; Figure 1B). Poor performance status
(P = 0.016), advanced stage (P = 0.041), number of extra-
nodal sites involved ≥ 2 (P = 0.003), bone marrow invol-
vement (P = 0.039), elevated LDH (P = 0.025), high IPI
scores (P < 0.001), and high PIT scores (P = 0.026) were
associated with a shorter PFS by univariate analysis. Of
these factors, high IPI scores (HR 2.43, 95% CI 1.51-3.90,
P < 0.001) and lymphopenia (HR 1.94, 95% CI 1.19-3.18,
P = 0.008) were significant independent prognostic fac-
tors for predicting PFS by multivariate analysis (Table 3).
Survival analysis of high-intermediate/high-risk IPI
patients
Forty-three (36.4%) patients were categorized as high-
intermediate/high risk by IPI scores. The median follow-
up duration was 8.1 months (range, 4.3-11.8 months).
Eighteen (41.9%) patients were in the low ALC group.
Thirty-three patients (76.7%) died during the follow-up
period. The TRM rate during first-line anthracycline-
containing chemotherapy was 4.0% (1 of 25 patients) in
the high ALC group and 38.8% (7 of 18 patients) in the
low ALC group (P = 0.006). The 3-year estimate for OS
was 20.1% and for PFS was 17.9%. The median OS was
longer in patients in the high ALC group–10.6 months
(range, 3.9-17.2 months) versus 4.0 months (range, 1.1-6.8
months) in the low ALC group (P = 0.002). Lymphopenia
was also independently associated with an unfavorable
Figure 1 Overall survival (A, P = 0.003) and progression free survival (B, P = 0.012) according to absolute lymphocyte count (ALC).
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impact on OS (HR 3.09, 95% CI 1.52-6.32, P = 0.002) and
PFS (HR 4.01, 95% CI 1.80-9.00, P = 0.001; Figures 2A and
2B). No other variables were significantly associated with
OS or PFS by univariate analysis (Table 4).
Discussion
This study found that lymphopenia is an unfavorable
prognostic factor for patients with PTCL-NOS treated
with anthracycline-containing chemotherapy. Higher IPI
Table 2 Univariate analysis for overall survival and progression free survival in patients with PTCL-NOS
Median OS, months HR (95% CI) P-value Median PFS, months HR (95% CI) P-value
Age
< 60 years 69.4 1.54 (0.92-2.58) 0.100 11.9 1.00 (0.62-1.62) 0.976
≥ 60 years 18.9 13.8
Gender
Male 30.0 1.24 (0.73-2.11) 0.422 12.1. 0.91 (0.55-1.51) 0.732
Female 27.5 15.2
Performance status
0-1 57.4 4.09 (2.10-8.00) < 0.001 14.5 2.28 (1.16-4.46) 0.016
2-4 6.3 3.6
B symptom
Absent 38.5 1.45 (0.84-2.50) 0.178 14.7 1.31 (0.79-2.16) 0.282
Present 15.6 7.1
Stage
1-2 69.4 1.63 (0.93-2.87) 0.086 19.1 1.68 (1.02-2.77) 0.041
3-4 16.6 9.5
Extranodal involvement
0-1 69.4 2.10 (1.24-3.54) 0.005 18.1 2.08 (1.29-3.35) 0.003
≥ 2 11.5 8.1
Bone marrow involvement
Negative 57.4 1.62 (0.93-2.79) 0.084 14.5 1.68 (1.02-2.76) 0.039
Positive 10.2 7.3
LDH
Normal NR 2.89 (1.67-5.00) < 0.001 16.0 1.69 (1.06-2.68) 0.025
Elevated 11.5 8.8
IPI
L, LI NR 3.96 (2.36-6.66) < 0.001 18.1 2.34 (1.47-3.74) < 0.001
HI, H 8.1 8.1
PIT
Group 1-2 76.1 2.78 (1.67-4.62) < 0.001 15.2 1.69 (1.06-2.69) 0.026
Group 3-4 10.1 9.4
ALC
≥ 1.0 × 109/l 69.4 2.19 (1.30-3.67) 0.003 18.1 3.01 (1.14-3.02) 0.012
< 1.0 × 109/l 15.5 7.0
LDH, lactate dehydrogenase; IPI, International Prognostic Index; L, low; LI, low-intermediate; HI, high-intermediate; H, high; PIT, Prognostic Index for peripheral T-
cell lymphoma; ALC, absolute lymphocyte count; NR, not reached; OS, overall survival; PFS, progression free survival.
Table 3 Multivariate analysis for overall survival and progression free survival in patients with PTCL- NOS
OS
P-value
HR (95% CI) PFS
P-value
HR (95% CI)
IPI
L, LI < 0.001 4.06 (95% CI 2.40-6.84) < 0.001 2.43 (95% CI 1.51-3.90)
HI, H
ALC
≥ 1.0 × 109/l 0.002 2.24 (95% CI 1.33-3.78) 0.008 1.94 (95% CI 1.19-3.18)
< 1.0 × 109/l
IPI, International Prognostic Index; L, low; LI, low-intermediate; HI, high-intermediate; H, high; ALC, absolute lymphocyte count; OS, overall survival; PFS,
progression free survival.
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scores and lymphopenia prior to chemotherapy were
independent prognostic factors for shorter OS and PFS
in these patients. Lymphopenia was frequently observed
in patients with elevated LDH, high-intermediate/high
risk IPI scores, and high PIT scores (P = 0.031, P =
0.043, P = 0.010, respectively). However, lymphopenia
had a significant role in identifying subgroups with a
poorer prognosis among patients at high-risk according
to IPI scores; in these patients, lymphopenia was asso-
ciated with significantly shorter OS and PFS (P = 0.003,
P = 0.012, respectively).
Both IPI and PIT scores have been used as important
prognostic factors in PTCL [6,9]. Recently, IPI scores
were found to be the most reliable factor in predicting
survival, but PIT scores had no significant prognostic
role according to the IPTCLP [24]. However, the prog-
nostic value of both these factors were studied regardless
of the type of systemic chemotherapy. Moreover, no
parameters were used to predict treatment outcomes or
further stratify patients with the same IPI scores. Castillo
et al. reported that a PIT score > 2 and lymphopenia
were independent prognostic factors for predicting a
poor response to therapy and survival in 69 patients with
PTCL-NOS [25]. However, this study included only 37
patients who were treated with systemic chemotherapy
[25]. Therefore, there was insufficient evidence to deter-
mine the prognostic role of lymphopenia in PTCL-NOS.
According to our data, 53.3% (8 of 15) of untreated
patients did not receive chemotherapy because of poor
performance status, and 60.0% (9 of 15) of these patients
had lymphopenia at diagnosis. Poor performance status
and lymphopenia might be frequently observed in
patients who do not receive chemotherapy. Therefore,
any analysis of the prognostic role of lymphopenia should
be performed only among patients who receive similar
systemic chemotherapy. In our study, we enrolled
patients newly diagnosed with PTCL-NOS who were
treated with anthracycline-containing chemotherapy as
first-line treatment and excluded patients who did not
receive any treatment or who received up-front ASCT.
Therefore, patients enrolled in our study may be more
homogenous compared with patients from previous stu-
dies and may be more appropriate for evaluating prog-
nostic factors.
The causes for lymphopenia are multi-factorial and its
consequences are heterogeneous. First of all, lymphopenia
could be related to inflammation, a condition usually
accompanied by relative neutrophilia or absolute lympho-
penia. In certain situations, inflammatory mediators seem
to play an important role in the development and progres-
sion of cancers [26]. There are some reports on the rela-
tionship between inflammation and cancer treatment
outcomes via the transcription factors NF-B in PTCL
[11,27]. In our study, lymphopenia was not simply a result
of impairment of bone marrow function, because there
was no significant difference in bone marrow involvement
between ALC groups (P = 0.578). It could be suggested
that lymphopenia may be related to higher tumor burden
and increased inflammatory mediators because we found
that lymphopenia was closely related to elevated LDH,
Figure 2 Overall survival (A, P = 0.002) and progression free survival (B, P = 0.001) according to absolute lymphocyte count (ALC) in
PTCL, NOS patients with high-intermediate/high risk IPI.
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high-intermediate/high risk IPI scores, and high PIT
scores. However, there may be other clinical meanings of
lymphopenia besides tumor burden, since lymphopenia
was an independent prognostic factor even among patients
classified as high-intermediate/high risk based on IPI
scores.
ALC is a surrogate marker of host immunity. Because
lymphopenia is reflective of a damaged immune system,
patients with lymphopenia usually showed poor res-
ponse and survival rates [25]. Previous studies have
explained why low ALCs might be related to immune
suppression or be a consequence of lymphocytic cyto-
kines produced by lymphoma cells [18]. Plonquet et al.
reported that a low NK cell count was related to a poor
response to chemotherapy in patients with DLBCL trea-
ted with rituximab [28]. CD4 lymphopenia is known to
be an independent risk factor for febrile neutropenia
and early death in cancer patients receiving cytotoxic
chemotherapy [29]. Therefore, lymphopenia may
increase a patient’s vulnerability to infection during che-
motherapy. Infection-related mortality is a main cause
of death during the chemotherapy for lymphoma. In our
study, TRM during first-line anthracycline-containing
chemotherapy was significantly higher in patients with
low ALCs compared to those with high ALCs (25.0% vs.
4.8%, P = 0.003), even though there was no difference in
the treatment response rates between the 2 groups (P =
0.154). Therefore, survival differences according to the
ALC are not associated with a poor response to che-
motherapy, but rather to a high rate of early mortality
during the chemotherapy. In conclusion, chemotherapy
regimens should be carefully selected for patients with
PTCL-NOS and lymphopenia in order to reduce TRM
during first-line chemotherapy. Newly developed tar-
geted agents or cellular therapy for treatment of these
patients should be considered in the future.
Table 4 Univariate analysis for overall survival and progression free survival in high-intermediate and high risk IPI
patients
Median OS, months HR (95% CI) P-value Median PFS, months HR (95% CI) P-value
Age
< 60 years 7.0 0.79 (0.39-1.61) 0.512 2.9 0.50 (0.24-1.01) 0.059
≥ 60 years 9.2 9.6
Gender
Male 10.1 1.33 (0.64-2.76) 0.444 8.1 1.07 (0.29-2.29) 0.862
Female 5.2 3.5
Performance status
0-1 10.1 1.72 (0.79-3.73) 0.168 8.1 1.15 (0.51-2.59) 0.728
2-4 4.8 3.6
B symptom
Absent 9.2 1.29 (0.62-2.66) 0.490 8.1 1.09 (0.51-2.33) 0.810
Present 7.0 3.6
Stage
1-2 4.0 0.21(0.02-0.72) 0.147 3.6 0.45 (0.05-3.44) 0.445
3-4 9.2 8.1
Extranodal involvement
0-1 10.1 1.13 (0.56-2.28) 0.729 14.7 1.27 (0.61-2.67) 0.518
≥ 2 8.1 3.9
Bone marrow involvement
Negative 11.9 1.33 (0.66-2.67) 0.414 9.5 1.29 (0.64-2.61) 0.467
Positive 7.3 7.0
LDH
Normal 9.2 1.51 (0.45-4.97) 0.498 8.1 1.54 (0.46-5.10) 0.474
Elevated 7.6 7.3
PIT
Group 1-2 16.9 1.35 (0.58-3.14) 0.476 8.1 1.06 (0.45-2.48) 0.883
Group 3-4 7.6 7.3
ALC
≥ 1.0 × 109/l 10.6 3.09 (1.52-6.32) 0.002 11.9 4.02 (1.80-8.97) 0.001
< 1.0 × 109/l 4.0 2.9
LDH, lactate dehydrogenase; IPI, International Prognostic Index; L, low; LI, low-intermediate; HI, high-intermediate; H, high; PIT, Prognostic Index for peripheral T-
cell lymphoma; ALC, absolute lymphocyte count; OS, overall survival; PFS, progression free survival.
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Furthermore, lymphocyte analysis at the time of diagno-
sis could clarify the role of lymphopenia in PTCL-NOS.
Although IPI scores showed a significant role for predict-
ing survival, ALC–a simple and easily obtainable test–was
also found to have an independent role in predicting survi-
val of patients with PTCL-NOS. Therefore, a lymphocyte
count should be recommended as a standard test before
initiation of first-line chemotherapy for PTCL-NOS.
Our study has some limitations. Because this study was
conducted retrospectively, treatment regimens were not
identical. To overcome this problem, we enrolled a rela-
tively large number of patients newly diagnosed with
PTCL-NOS who were treated with anthracycline-contain-
ing chemotherapy as first-line treatment. In this regard,
large-scale, prospective studies are required to confirm the
prognostic value of lymphopenia compared to other biolo-
gic tests, such as immunophenotyping or gene expression
profiling. In addition, we did not perform a review of the
pathology of each case, since cases had already been
reviewed by experienced hematopathologists from each
institution.
In conclusion, we found that lymphopenia was an inde-
pendent prognostic factor for poor OS and PFS in
patients with PTCL-NOS treated with anthracycline-con-
taining chemotherapy. Lymphopenia was also a useful
marker for further stratification of patients at high risk
based on IPI scores. Further efforts to reduce TRM and
new strategies to improve OS are needed, especially in
patients with PTCL-NOS and lymphopenia.
Acknowledgements
This study was supported by a faculty research grant of Yonsei University
College of Medicine for 2010 (6-2010-0065). Presented in abstract form at
the 52nd annual meeting of the American Society of Hematology, Orlando,
FL, December 4-7, 2010.
Author details
1Division of Hematology, Department of Internal Medicine, Yonsei University
College of Medicine, Seoul, 120-752, Korea. 2Division of Hematology/
Oncology, Department of Medicine, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Seoul, 135-710, Korea.
3Hematology-Oncology Clinic, Center for Specific Organs Cancer, National
Cancer Center, Goyang, 410-769, Korea. 4Department of Hematology-
Oncology, Ajou University School of Medicine, Suwon, 443-749, Korea.
Authors’ contributions
YRK involved in conception, design, data interpretation, and manuscript
writing. JSK performed data interpretation and revising it critically for
intellectual content. SJK involved in acquisition of data, analysis of data. HAJ
involved in acquisition of data, analysis of data. SJK involved in acquisition of
data, analysis of data and participating in comprehensive discussion. WSK
involved in analysis of data and participating in comprehensive discussion.
HWL involved in acquisition of data, analysis of data. HSE involved in
acquisition of data, analysis of data and participating in comprehensive
discussion. SHJ involved in acquisition of data, analysis of data and
participating in comprehensive discussion. JSP involved in acquisition of
data, analysis of data and participating in comprehensive discussion. JWC
involved analysis of data and participating in comprehensive discussion.
YHM involved in analysis of data and participating in comprehensive
discussion. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 30 July 2011 Accepted: 15 August 2011
Published: 15 August 2011
References
1. Savage KJ: Peripheral T-cell lymphomas. Blood reviews 2007, 21:201-216.
2. Vose J, Armitage J, Weisenburger D: International peripheral T-cell and
natural killer/T-cell lymphoma study: pathology findings and clinical
outcomes. Journal of clinical oncology 2008, 26:4124-4130.
3. Agostinelli C, Piccaluga PP, Went P, Rossi M, Gazzola A, Righi S, Sista T,
Campidelli C, Zinzani PL, Falini B, Pileri SA: Peripheral T cell lymphoma,
not otherwise specified: the stuff of genes, dreams and therapies.
Journal of Clinical Pathology 2008, 61:1160-1167.
4. Rizvi MA, Evens AM, Tallman MS, Nelson BP, Rosen ST: T-cell non-Hodgkin
lymphoma. Blood 2006, 107:1255-1264.
5. Escaln MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL, Dang NH:
Prognostic factors and treatment of patients with T-cell non-Hodgkin
lymphoma: the M. D. Anderson Cancer Center experience. Cancer 2005,
103:2091-2098.
6. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, Morabito F,
Martelli M, Brusamolino E, Iannitto E, et al: Peripheral T-cell lymphoma
unspecified (PTCL-U): a new prognostic model from a retrospective
multicentric clinical study. Blood 2004, 103:2474-2479.
7. Gutirrez-Garca G, Garca-Herrera A, Cardesa T, Martnez A, Villamor N, Ghita G,
Martnez-Trillos A, Colomo L, Setoain X, Rodrguez S, et al: Comparison of
four prognostic scores in peripheral T-cell lymphoma. Annals of oncology
2011, 22:397-404.
8. Vose JM: International Peripheral T-Cell Lymphoma (PTCL) Clinical and
Pathologic Review Project: Poor Outcome by Prognostic Indices and
Lack of Efficacy with Anthracyclines. Blood 2005, 106:811a.
9. A predictive model for aggressive non-Hodgkin’s lymphoma. The
International Non-Hodgkin’s Lymphoma Prognostic Factors Project. The
New England journal of medicine 1993, 329:987-994.
10. Martinez Delgado B, Melndez B, Cuadros M, Alvarez J, Castrillo JM, Ruiz De
La Parte A, Mollejo M, Bellas C, Diaz R, Lombarda L, et al: Expression
profiling of T-cell lymphomas differentiates peripheral and
lymphoblastic lymphomas and defines survival related genes. Clinical
cancer research 2004, 10:4971-4982.
11. Martnez-Delgado B, Cuadros M, Honrado E, Ruiz de la Parte A, Roncador G,
Alves J, Castrillo JM, Rivas C, Bentez J: Differential expression of NF-
kappaB pathway genes among peripheral T-cell lymphomas. Leukemia
2005, 19:2254-2263.
12. Rodrguez-Antona C, Leskel S, Zajac M, Cuadros M, Alvs J, Moneo MV,
Martn C, Cigudosa JC, Carnero A, Robledo M, et al: Expression of CYP3A4
as a predictor of response to chemotherapy in peripheral T-cell
lymphomas. Blood 2007, 110:3345-3351.
13. Cox MC, Nofroni I, Laverde G, Ferrari A, Amodeo R, Tatarelli C, Saltarelli F,
Veggia B, Aloe-Spiriti MA, Ruco L, Monarca B: Absolute lymphocyte count
is a prognostic factor in diffuse large B-cell lymphoma. British journal of
haematology 2008, 141:265-268.
14. Cox MC, Nofroni I, Ruco L, Amodeo R, Ferrari A, La Verde G, Cardelli P,
Montefusco E, Conte E, Monarca B, Aloe-Spiriti MA: Low absolute
lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-
lymphoma. Leukemia & lymphoma 2008, 49:1745-1751.
15. Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y, Morishima Y:
Low absolute lymphocyte count is a poor prognostic marker in patients
with diffuse large B-cell lymphoma and suggests patients’ survival
benefit from rituximab. European journal of haematology 2008, 81:448-453.
16. Kim DH, Baek JH, Chae YS, Kim YK, Kim HJ, Park YH, Song HS, Chung JS,
Hyun MS, Sohn SK: Absolute lymphocyte counts predicts response to
chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia
2007, 21:2227-2230.
17. Behl D, Ristow K, Markovic SN, Witzig TE, Habermann TM, Colgan JP,
Inwards DJ, White WL, Ansell SM, Micallef IN, et al: Absolute lymphocyte
count predicts therapeutic efficacy of rituximab therapy in follicular
lymphomas. British journal of haematology 2007, 137:409-415.
18. Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I,
Tredan O, Verweij J, Biron P, Labidi I, et al: Lymphopenia as a prognostic
Kim et al. Journal of Hematology & Oncology 2011, 4:34
http://www.jhoonline.org/content/4/1/34
Page 8 of 9
factor for overall survival in advanced carcinomas, sarcomas, and
lymphomas. Cancer research 2009, 69:5383-5391.
19. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin’s
disease. International Prognostic Factors Project on Advanced Hodgkin’s
Disease. The New England journal of medicine 1998, 339:1506-1514.
20. Porrata LF, Rsitow K, Inwards DJ, Ansell SM, Micallef IN, Johnston PB,
Habermann TM, Witzig TE, Colgan JP, Nowakowski GS, et al: Lymphopenia
assessed during routine follow-up after immunochemotherapy (R-CHOP)
is a risk factor for predicting relapse in patients with diffuse large B-cell
lymphoma. Leukemia 2010, 24:1343-1349.
21. Porrata LF, Ristow K, Habermann TM, Witzig TE, Inwards DJ, Markovic SN:
Absolute lymphocyte count at the time of first relapse predicts survival
in patients with diffuse large B-cell lymphoma. American journal of
hematology 2009, 84:93-97.
22. Huang JJ, Jiang WQ, Lin TY, Huang Y, Xu RH, Huang HQ, Li ZM: Absolute
lymphocyte count is a novel prognostic indicator in extranodal natural
killer/T-cell lymphoma, nasal type. Annals of oncology 2011, 22:149-155.
23. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM,
Lister TA, Vose J, Grillo-Lpez A, Hagenbeek A, et al: Report of an
international workshop to standardize response criteria for non-
Hodgkin’s lymphomas. NCI Sponsored International Working Group.
Journal of clinical oncology 1999, 17:1244-1244.
24. Weisenburger D, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES,
Maclennan KA, Rdiger T, Pileri S, Nakamura S, Nathwani B, et al: Peripheral
T-cell lymphoma, not otherwise specified: a report of 340 cases from
the International Peripheral T-cell Lymphoma Project. Blood 2011,
117:3402-3408.
25. Castillo J, Morales D, Quinones P, Cotrina E, Desposorio C, Beltran B:
Lymphopenia as a prognostic factor in patients with peripheral T-cell
lymphoma, unspecified. Leukemia & lymphoma 2010, 51:1822-1828.
26. Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N, Clarke SJ:
High blood neutrophil-to-lymphocyte ratio is an indicator of poor
prognosis in malignant mesothelioma patients undergoing systemic
therapy. Clinical cancer research 2010, 16:5805-5813.
27. Porta C, Larghi P, Rimoldi M, Totaro MG, Allavena P, Mantovani A, Sica A:
Cellular and molecular pathways linking inflammation and cancer.
Immunobiology 2009, 214:761-777.
28. Plonquet A, Haioun C, Jais JP, Debard AL, Salles G, Bene MC, Feugier P,
Rabian C, Casasnovas O, Labalette M, et al: Peripheral blood natural killer
cell count is associated with clinical outcome in patients with aaIPI 2-3
diffuse large B-cell lymphoma. Annals of oncology 2007, 18:1209-1215.
29. Borg C, Ray Coquard I, Philip I, Clapisson G, Bendriss Vermare N, Menetrier
Caux C, Sebban C, Biron P, Blay J: CD4 lymphopenia as a risk factor for
febrile neutropenia and early death after cytotoxic chemotherapy in
adult patients with cancer. Cancer 2004, 101:2675-2680.
doi:10.1186/1756-8722-4-34
Cite this article as: Kim et al.: Lymphopenia is an important prognostic
factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-
containing chemotherapy. Journal of Hematology & Oncology 2011 4:34.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kim et al. Journal of Hematology & Oncology 2011, 4:34
http://www.jhoonline.org/content/4/1/34
Page 9 of 9
